Skip to main content
Top
Published in: Diabetologia 5/2008

Open Access 01-05-2008 | Review

What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?

Authors: S. C. Satchell, J. E. Tooke

Published in: Diabetologia | Issue 5/2008

Login to get access

Abstract

Microalbuminuria is an important risk factor for cardiovascular disease and progressive renal impairment. This holds true in the general population and particularly in those with diabetes, in whom it is common and marks out those likely to develop macrovascular disease and progressive renal impairment. Understanding the pathophysiological mechanisms through which microalbuminuria occurs holds the key to designing therapies to arrest its development and prevent these later manifestations.
Microalbuminuria arises from the increased passage of albumin through the glomerular filtration barrier. This requires ultrastructural changes rather than alterations in glomerular pressure or filtration rate alone. Compromise of selective glomerular permeability can be confirmed in early diabetic nephropathy but does not correlate well with reported glomerular structural changes. The loss of systemic endothelial glycocalyx—a protein-rich surface layer on the endothelium—in diabetes suggests that damage to this layer represents this missing link. The epidemiology of microalbuminuria reveals a close association with systemic endothelial dysfunction and with vascular disease, also implicating glomerular endothelial dysfunction in microalbuminuria.
Our understanding of the metabolic and hormonal sequelae of hyperglycaemia is increasing, and we consider these in the context of damage to the glomerular filtration barrier. Reactive oxygen species, inflammatory cytokines and growth factors are key players in this respect. Taken together with the above observations and the presence of generalised endothelial dysfunction, these considerations lead to the conclusion that glomerular endothelial dysfunction, and in particular damage to its glycocalyx, represents the most likely initiating step in diabetic microalbuminuria.
Literature
1.
go back to reference Stehouwer CD, Smulders YM (2006) Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 17:2106–2111PubMedCrossRef Stehouwer CD, Smulders YM (2006) Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 17:2106–2111PubMedCrossRef
2.
go back to reference Warram JH, Gearin G, Laffel L, Krolewski AS (1996) Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930–937PubMed Warram JH, Gearin G, Laffel L, Krolewski AS (1996) Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930–937PubMed
3.
go back to reference Mogensen CE, Poulsen PL (1994) Epidemiology of microalbuminuria in diabetes and in the background population. Curr Opin Nephrol Hypertens 3:248–256PubMedCrossRef Mogensen CE, Poulsen PL (1994) Epidemiology of microalbuminuria in diabetes and in the background population. Curr Opin Nephrol Hypertens 3:248–256PubMedCrossRef
4.
go back to reference Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219–226PubMedCrossRef Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219–226PubMedCrossRef
5.
go back to reference Parving HH (1996) Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl 14:S89–S93 discussion S93–S84PubMedCrossRef Parving HH (1996) Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl 14:S89–S93 discussion S93–S84PubMedCrossRef
6.
go back to reference Bianchi S, Bigazzi R, Campese VM (1999) Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 34:973–995PubMedCrossRef Bianchi S, Bigazzi R, Campese VM (1999) Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 34:973–995PubMedCrossRef
7.
go back to reference Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K (2000) Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35:898–903PubMed Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K (2000) Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35:898–903PubMed
8.
go back to reference Schalkwijk CG, Stehouwer CD (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143–159CrossRef Schalkwijk CG, Stehouwer CD (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143–159CrossRef
9.
go back to reference De Gaudio AR, Adembri C, Grechi S, Novelli GP (2000) Microalbuminuria as an early index of impairment of glomerular permeability in postoperative septic patients. Intensive Care Med 26:1364–1368PubMedCrossRef De Gaudio AR, Adembri C, Grechi S, Novelli GP (2000) Microalbuminuria as an early index of impairment of glomerular permeability in postoperative septic patients. Intensive Care Med 26:1364–1368PubMedCrossRef
10.
go back to reference Mahmud N, O’Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D (1995) Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 7:215–219PubMed Mahmud N, O’Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D (1995) Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 7:215–219PubMed
11.
go back to reference Hillege HL, Janssen WM, Bak AA et al (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249:519–526PubMedCrossRef Hillege HL, Janssen WM, Bak AA et al (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249:519–526PubMedCrossRef
12.
go back to reference Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT (2001) Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 161:2000–2005PubMedCrossRef Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT (2001) Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 161:2000–2005PubMedCrossRef
13.
go back to reference Sowers JR, Epstein M, Frohlich ED (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37:1053–1059PubMed Sowers JR, Epstein M, Frohlich ED (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37:1053–1059PubMed
14.
go back to reference Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH (2001) Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60:277–283PubMedCrossRef Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH (2001) Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60:277–283PubMedCrossRef
15.
go back to reference Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef
16.
go back to reference Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945PubMedCrossRef Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945PubMedCrossRef
17.
go back to reference Campos-Pastor MM, Escobar-Jimenez F, Mezquita P et al (2000) Factors associated with microalbuminuria in type 1 diabetes mellitus: a cross-sectional study. Diabetes Res Clin Pract 48:43–49PubMedCrossRef Campos-Pastor MM, Escobar-Jimenez F, Mezquita P et al (2000) Factors associated with microalbuminuria in type 1 diabetes mellitus: a cross-sectional study. Diabetes Res Clin Pract 48:43–49PubMedCrossRef
18.
go back to reference Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G (1993) Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883–887PubMedCrossRef Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G (1993) Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883–887PubMedCrossRef
19.
go back to reference Rossing P, Hougaard P, Borch-Johnsen K, Parving HH (1996) Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 313:779–784PubMed Rossing P, Hougaard P, Borch-Johnsen K, Parving HH (1996) Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 313:779–784PubMed
20.
go back to reference Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin- dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418PubMedCrossRef Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin- dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418PubMedCrossRef
21.
go back to reference Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS (1999) Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992–1997PubMed Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS (1999) Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992–1997PubMed
22.
go back to reference Fioretto P, Stehouwer CD, Mauer M et al (1998) Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 41:233–236PubMedCrossRef Fioretto P, Stehouwer CD, Mauer M et al (1998) Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 41:233–236PubMedCrossRef
23.
go back to reference Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232PubMedCrossRef Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232PubMedCrossRef
24.
go back to reference Parving HH, Chaturvedi N, Viberti G, Mogensen CE (2002) Does microalbuminuria predict diabetic nephropathy. Diabetes Care 25:406–407PubMedCrossRef Parving HH, Chaturvedi N, Viberti G, Mogensen CE (2002) Does microalbuminuria predict diabetic nephropathy. Diabetes Care 25:406–407PubMedCrossRef
25.
go back to reference Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426PubMedCrossRef Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426PubMedCrossRef
26.
go back to reference Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM (2004) Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction—the Hoorn Study. Kidney Int Suppl:S42–S44CrossRef Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM (2004) Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction—the Hoorn Study. Kidney Int Suppl:S42–S44CrossRef
27.
go back to reference Schalkwijk CG, Poland DC, van Dijk W et al (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357PubMedCrossRef Schalkwijk CG, Poland DC, van Dijk W et al (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357PubMedCrossRef
28.
go back to reference Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109:II2–II10PubMed Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109:II2–II10PubMed
29.
go back to reference Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ (1995) Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 44:561–564PubMedCrossRef Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ (1995) Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 44:561–564PubMedCrossRef
30.
go back to reference Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157–1165PubMedCrossRef Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157–1165PubMedCrossRef
31.
go back to reference Deen WM, Lazzara MJ, Myers BD (2001) Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 281:F579–F596PubMed Deen WM, Lazzara MJ, Myers BD (2001) Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 281:F579–F596PubMed
32.
go back to reference Ballermann BJ (2007) Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 106:p19–p25PubMedCrossRef Ballermann BJ (2007) Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 106:p19–p25PubMedCrossRef
33.
go back to reference Rostgaard J, Qvortrup K (1997) Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res 53:1–13PubMedCrossRef Rostgaard J, Qvortrup K (1997) Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res 53:1–13PubMedCrossRef
34.
go back to reference Hjalmarsson C, Johansson BR, Haraldsson B (2004) Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res 67:9–17PubMedCrossRef Hjalmarsson C, Johansson BR, Haraldsson B (2004) Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res 67:9–17PubMedCrossRef
35.
go back to reference Huxley VH, Williams DA (2000) Role of a glycocalyx on coronary arteriole permeability to proteins: evidence from enzyme treatments. Am J Physiol Heart Circ Physiol 278:H1177–H1185PubMed Huxley VH, Williams DA (2000) Role of a glycocalyx on coronary arteriole permeability to proteins: evidence from enzyme treatments. Am J Physiol Heart Circ Physiol 278:H1177–H1185PubMed
36.
go back to reference Rehm M, Zahler S, Lotsch M et al (2004) Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology 100:1211–1223PubMedCrossRef Rehm M, Zahler S, Lotsch M et al (2004) Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology 100:1211–1223PubMedCrossRef
37.
go back to reference Levick JR, Smaje LH (1987) An analysis of the permeability of a fenestra. Microvasc Res 33:233–256PubMedCrossRef Levick JR, Smaje LH (1987) An analysis of the permeability of a fenestra. Microvasc Res 33:233–256PubMedCrossRef
38.
go back to reference Ohlson M, Sorensson J, Haraldsson B (2001) A gel-membrane model of glomerular charge and size selectivity in series. Am J Physiol Renal Physiol 280:F396–H405PubMed Ohlson M, Sorensson J, Haraldsson B (2001) A gel-membrane model of glomerular charge and size selectivity in series. Am J Physiol Renal Physiol 280:F396–H405PubMed
39.
go back to reference Jeansson M, Haraldsson B (2006) Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 290:F111–H116PubMedCrossRef Jeansson M, Haraldsson B (2006) Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 290:F111–H116PubMedCrossRef
40.
go back to reference Ryan GB, Karnovsky MJ (1976) Distribution of endogenous albumin in the rat glomerulus: role of hemodynamic factors in glomerular barrier function. Kidney Int 9:36–45PubMedCrossRef Ryan GB, Karnovsky MJ (1976) Distribution of endogenous albumin in the rat glomerulus: role of hemodynamic factors in glomerular barrier function. Kidney Int 9:36–45PubMedCrossRef
41.
go back to reference Henry CB, Duling BR (2000) TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 279:H2815–H2823PubMed Henry CB, Duling BR (2000) TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 279:H2815–H2823PubMed
42.
go back to reference Yoshioka T, Ichikawa I, Fogo A (1991) Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 2:902–912PubMed Yoshioka T, Ichikawa I, Fogo A (1991) Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 2:902–912PubMed
43.
go back to reference Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathieson PW (2007) Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 18:2885–2893PubMedCrossRef Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathieson PW (2007) Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 18:2885–2893PubMedCrossRef
44.
go back to reference Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83:253–307PubMed Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83:253–307PubMed
45.
go back to reference Haraldsson B, Sorensson J (2004) Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci 19:7–10PubMed Haraldsson B, Sorensson J (2004) Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci 19:7–10PubMed
46.
go back to reference Drumond MC, Deen WM (1994) Structural determinants of glomerular hydraulic permeability. Am J Physiol 266:F1–F12PubMed Drumond MC, Deen WM (1994) Structural determinants of glomerular hydraulic permeability. Am J Physiol 266:F1–F12PubMed
47.
go back to reference Lazzara MJ, Deen WM (2007) Model of albumin reabsorption in the proximal tubule. Am J Physiol Renal Physiol 292:F430–F439PubMedCrossRef Lazzara MJ, Deen WM (2007) Model of albumin reabsorption in the proximal tubule. Am J Physiol Renal Physiol 292:F430–F439PubMedCrossRef
48.
go back to reference Ohlson M, Sorensson J, Lindstrom K, Blom AM, Fries E, Haraldsson B (2001) Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol Renal Physiol 281:F103–F113PubMed Ohlson M, Sorensson J, Lindstrom K, Blom AM, Fries E, Haraldsson B (2001) Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol Renal Physiol 281:F103–F113PubMed
49.
go back to reference Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P (2000) Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26(Suppl 4):8–14PubMed Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P (2000) Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26(Suppl 4):8–14PubMed
50.
go back to reference Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P (2003) Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52:1031–1035PubMedCrossRef Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P (2003) Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52:1031–1035PubMedCrossRef
51.
go back to reference Pagtalunan ME, Miller PL, Jumping-Eagle S et al (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342–348PubMedCrossRef Pagtalunan ME, Miller PL, Jumping-Eagle S et al (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342–348PubMedCrossRef
52.
go back to reference Osterby R, Asplund J, Bangstad HJ et al (1999) Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14:348–352PubMedCrossRef Osterby R, Asplund J, Bangstad HJ et al (1999) Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14:348–352PubMedCrossRef
53.
go back to reference Kanesaki Y, Suzuki D, Uehara G et al (2005) Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45:288–294PubMedCrossRef Kanesaki Y, Suzuki D, Uehara G et al (2005) Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45:288–294PubMedCrossRef
54.
go back to reference Nieuwdorp M, van Haeften TW, Gouverneur MC et al (2006) Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 55:480–486PubMedCrossRef Nieuwdorp M, van Haeften TW, Gouverneur MC et al (2006) Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 55:480–486PubMedCrossRef
55.
go back to reference Nieuwdorp M, Mooij HL, Kroon J et al (2006) Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55:1127–1132PubMedCrossRef Nieuwdorp M, Mooij HL, Kroon J et al (2006) Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55:1127–1132PubMedCrossRef
56.
go back to reference van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S (2004) Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 66:1901–1906PubMedCrossRef van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S (2004) Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 66:1901–1906PubMedCrossRef
57.
go back to reference Karumanchi SA, Epstein FH, Stillman IE (2005) Is loss of podocyte foot processes necessary for the induction of proteinuria. Am J Kidney Dis 45:436PubMedCrossRef Karumanchi SA, Epstein FH, Stillman IE (2005) Is loss of podocyte foot processes necessary for the induction of proteinuria. Am J Kidney Dis 45:436PubMedCrossRef
58.
go back to reference Lemley KV, Blouch K, Abdullah I et al (2000) Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 11:2095–2105PubMed Lemley KV, Blouch K, Abdullah I et al (2000) Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 11:2095–2105PubMed
59.
go back to reference White KE, Bilous RW, Marshall SM et al (2002) Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51:3083–3089PubMedCrossRef White KE, Bilous RW, Marshall SM et al (2002) Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51:3083–3089PubMedCrossRef
60.
go back to reference Carraro M, Mancini W, Artero M et al (2000) Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. Diabetologia 43:235–241PubMedCrossRef Carraro M, Mancini W, Artero M et al (2000) Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. Diabetologia 43:235–241PubMedCrossRef
61.
go back to reference Jeansson M, Granqvist AB, Nystrom JS, Haraldsson B (2006) Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice. Diabetologia 49:2200–2209PubMedCrossRef Jeansson M, Granqvist AB, Nystrom JS, Haraldsson B (2006) Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice. Diabetologia 49:2200–2209PubMedCrossRef
62.
go back to reference Jensen JS, Borch-Johnsen K, Deckert T, Deckert M, Jensen G, Feldt-Rasmussen B (1995) Reduced glomerular size- and charge-selectivity in clinically healthy individuals with microalbuminuria. Eur J Clin Invest 25:608–614PubMedCrossRef Jensen JS, Borch-Johnsen K, Deckert T, Deckert M, Jensen G, Feldt-Rasmussen B (1995) Reduced glomerular size- and charge-selectivity in clinically healthy individuals with microalbuminuria. Eur J Clin Invest 25:608–614PubMedCrossRef
63.
go back to reference Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreasen HB, Feldt-Rasmussen B (1993) Size- and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36:244–251PubMedCrossRef Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreasen HB, Feldt-Rasmussen B (1993) Size- and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36:244–251PubMedCrossRef
64.
go back to reference Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020PubMedCrossRef Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020PubMedCrossRef
65.
go back to reference Wang A, Ziyadeh FN, Lee EY et al (2007) Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 293:F1657–F1665PubMedCrossRef Wang A, Ziyadeh FN, Lee EY et al (2007) Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 293:F1657–F1665PubMedCrossRef
66.
go back to reference Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
67.
go back to reference Kashihara N, Watanabe Y, Makino H, Wallner EI, Kanwar YS (1992) Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89:6309–6313PubMedCrossRef Kashihara N, Watanabe Y, Makino H, Wallner EI, Kanwar YS (1992) Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89:6309–6313PubMedCrossRef
68.
go back to reference Vink H, Duling BR (1996) Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 79:581–589PubMed Vink H, Duling BR (1996) Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 79:581–589PubMed
69.
go back to reference Satoh M, Fujimoto S, Haruna Y et al (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288:F1144–F1152PubMedCrossRef Satoh M, Fujimoto S, Haruna Y et al (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288:F1144–F1152PubMedCrossRef
70.
go back to reference DeRubertis FR, Craven PA, Melhem MF, Salah EM (2004) Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 53:762–768PubMedCrossRef DeRubertis FR, Craven PA, Melhem MF, Salah EM (2004) Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 53:762–768PubMedCrossRef
71.
go back to reference Duann P, Datta PK, Pan C, Blumberg JB, Sharma M, Lianos EA (2006) Superoxide dismutase mimetic preserves the glomerular capillary permeability barrier to protein. J Pharmacol Exp Ther 316:1249–1254PubMedCrossRef Duann P, Datta PK, Pan C, Blumberg JB, Sharma M, Lianos EA (2006) Superoxide dismutase mimetic preserves the glomerular capillary permeability barrier to protein. J Pharmacol Exp Ther 316:1249–1254PubMedCrossRef
72.
go back to reference Susztak K, Raff AC, Schiffer M, Bottinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233PubMedCrossRef Susztak K, Raff AC, Schiffer M, Bottinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233PubMedCrossRef
73.
go back to reference Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341–1348PubMed Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341–1348PubMed
74.
go back to reference Satchell SC, Tasman CH, Singh A et al (2006) Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 69:1633–1640PubMedCrossRef Satchell SC, Tasman CH, Singh A et al (2006) Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 69:1633–1640PubMedCrossRef
75.
go back to reference Cooper ME, Vranes D, Youssef S et al (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229–2239PubMedCrossRef Cooper ME, Vranes D, Youssef S et al (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229–2239PubMedCrossRef
76.
go back to reference de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12:993–1000PubMed de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12:993–1000PubMed
77.
go back to reference Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51:3090–3094PubMedCrossRef Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51:3090–3094PubMedCrossRef
78.
go back to reference Chiarelli F, Spagnoli A, Basciani F et al (2000) Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 17:650–656PubMedCrossRef Chiarelli F, Spagnoli A, Basciani F et al (2000) Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 17:650–656PubMedCrossRef
79.
go back to reference Kim NH, Oh JH, Seo JA et al (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 67:167–177PubMedCrossRef Kim NH, Oh JH, Seo JA et al (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 67:167–177PubMedCrossRef
80.
go back to reference Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP (2006) Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69:1654–1661PubMedCrossRef Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP (2006) Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69:1654–1661PubMedCrossRef
81.
go back to reference Eremina V, Sood M, Haigh J et al (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707–716PubMed Eremina V, Sood M, Haigh J et al (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707–716PubMed
82.
go back to reference Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX (2006) Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 17:475–486PubMedCrossRef Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX (2006) Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 17:475–486PubMedCrossRef
83.
go back to reference Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971–1010PubMedCrossRef Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971–1010PubMedCrossRef
84.
go back to reference Flyvbjerg A, Bornfeldt KE, Marshall SM, Arnqvist HJ, Orskov H (1990) Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia 33:334–338PubMedCrossRef Flyvbjerg A, Bornfeldt KE, Marshall SM, Arnqvist HJ, Orskov H (1990) Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia 33:334–338PubMedCrossRef
85.
go back to reference Gronbaek H, Vogel I, Osterby R, Lancranjan I, Flyvbjerg A, Orskov H (1998) Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. Kidney Int 53:173–180PubMedCrossRef Gronbaek H, Vogel I, Osterby R, Lancranjan I, Flyvbjerg A, Orskov H (1998) Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. Kidney Int 53:173–180PubMedCrossRef
86.
go back to reference Hovind P, Lamberts S, Hop W et al (2007) An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. Eur J Endocrinol 156:83–90PubMedCrossRef Hovind P, Lamberts S, Hop W et al (2007) An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. Eur J Endocrinol 156:83–90PubMedCrossRef
87.
go back to reference Clemens A, Klevesath MS, Hofmann M et al (1999) Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism 48:1236–1240PubMedCrossRef Clemens A, Klevesath MS, Hofmann M et al (1999) Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism 48:1236–1240PubMedCrossRef
88.
go back to reference Smith LE, Shen W, Perruzzi C et al (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390–1395 (java/Propub/medicine/nm1299_1390.fulltext java/Propub/medicine/nm1299_1390.abstract)PubMedCrossRef Smith LE, Shen W, Perruzzi C et al (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390–1395 (java/Propub/medicine/nm1299_1390.fulltext java/Propub/medicine/nm1299_1390.abstract)PubMedCrossRef
89.
go back to reference Friedl J, Puhlmann M, Bartlett DL et al (2002) Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100:1334–1339PubMed Friedl J, Puhlmann M, Bartlett DL et al (2002) Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100:1334–1339PubMed
90.
go back to reference Navarro JF, Milena FJ, Mora C et al (2005) Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 68:S98–S102CrossRef Navarro JF, Milena FJ, Mora C et al (2005) Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 68:S98–S102CrossRef
91.
go back to reference Moriwaki Y, Yamamoto T, Shibutani Y et al (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605–608PubMedCrossRef Moriwaki Y, Yamamoto T, Shibutani Y et al (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605–608PubMedCrossRef
92.
go back to reference Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407PubMedCrossRef Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407PubMedCrossRef
93.
go back to reference McMillan DE (1989) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38:1042–1046PubMedCrossRef McMillan DE (1989) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38:1042–1046PubMedCrossRef
94.
go back to reference Yang X, Smith U (2007) Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50:1127–1139PubMedCrossRef Yang X, Smith U (2007) Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50:1127–1139PubMedCrossRef
95.
go back to reference Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y (2001) Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A 98:6390–6395PubMedCrossRef Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y (2001) Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A 98:6390–6395PubMedCrossRef
96.
go back to reference Matsuda M, Kawasaki F, Yamada K et al (2004) Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. Diabet Med 21:881–888PubMedCrossRef Matsuda M, Kawasaki F, Yamada K et al (2004) Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. Diabet Med 21:881–888PubMedCrossRef
97.
98.
go back to reference Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B (1995) Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch) 88:629–633 Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B (1995) Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch) 88:629–633
Metadata
Title
What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?
Authors
S. C. Satchell
J. E. Tooke
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-0961-8

Other articles of this Issue 5/2008

Diabetologia 5/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.